Skip to main content

Advertisement

Fig. 2 | Experimental Hematology & Oncology

Fig. 2

From: The SMAC mimetic LCL-161 selectively targets JAK2V617F mutant cells

Fig. 2

JAK inhibitors rescue hypersensitivity of JAK2V617F mutant cells to LCL-161. L929 cells expressing JAK2WT, JAK2V617F or empty vector were incubated with increasing concentrations of a LCL-161 alone, b LCL-161 with the addition of 1 µM ruxolitinib, or c LCL-161 with the addition of 1 µM pacritinib. After 48 h in culture a resazurin-based cell viability assay was performed. ****P < 0.0001, 2way ANOVA

Back to article page